Thursday, October 15, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source documentYahoo Finance· March 9, 2026

OSB GROUP PLC - Transaction in Own Shares

View original at finance.yahoo.com
OSB GROUP PLC - Transaction in Own Shares OSB GROUP PLC OSB GROUP PLC ISIN: GB00BLDRH360 9 March 2026 LEI number: 213800ZBKL9BHSL2K459 OSB GROUP PLC (the “Company”) Share Buyback Programme – Transactions in Own Shares The Company announces that on 06 March 2026 it had purchased a total of 94,482 of its ordinary shares…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

Data points we hold from this source

OSB GROUP PLC · highest price paid585.50 GBp_per_share
OSB GROUP PLC · voting rights352568975 voting_shares
OSB GROUP PLC · lowest price paid568.00 GBp_per_share
OSB GROUP PLC · shares repurchased94482 ordinary_shares
OSB GROUP PLC · shares outstanding352568975 ordinary_shares
OSB GROUP PLC · treasury shares0 ordinary_shares
OSB GROUP PLC · vwap575.65 GBp_per_share
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com
OSB GROUP PLC - Transaction in Own Shares — Source | Via News | ViaNews Market